Novo wants to secure reputation through data access

Following increased public pressure the previously adamant drug industry has changed its tune, deciding to open its treasured clinical data vaults. But it is unlikely to result in crucial improvements for patients, says Novo Nordisk.

In March the two drug companies AbbVie and InterMune sued the EMA because the agency wanted to publish “classified” and “commercially sensitive” data on the companies’ drugs. And in June a Sanofi executive, who is also head of the European industry organisation EFPIA, threatened to move investments out of Europe because he was dissatisfied with the latest demands for data access.

But the collective drug industry now seems to have changed its tune. The US industri organisation PhRMA and European counterpart EFPIA has agreed to a number of principles for the industry to ensure that access to data is granted.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier